Phase 1 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign a consent form agreeing to take part in the study.
- You are able and willing to follow the study schedule and meet all the study requirements.
- You are between 18 and 60 years old (inclusive) at the time of signing the consent form.
- If you are female, you are not currently pregnant or breastfeeding.
- You have been diagnosed with PMS (Primary or Progressive Multiple Sclerosis — confirm with trial site).
- You have previously been treated with 2 disease-modifying therapies (medicines used to alter the course of your condition).
Who may not be able to join:
- You are currently taking certain medications that are not allowed under the study rules (confirm with trial site which medications are restricted).
- You have a highly active form of multiple sclerosis.
- You have been diagnosed with another autoimmune condition affecting the brain or spinal cord.
- You currently have an active or uncontrolled fungal, bacterial, or viral infection.
- You have a history of cancer, unless you have been free of the disease for at least 24 months.
- You have had a transplant of the heart, lungs, kidneys, liver, or blood stem cells at any point in the past.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +44 (0)203 911 4385
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of participants receiving obe-cel who experience dose-limiting toxicities (DLTs)); To evaluate the safety of obe-cel in participants with refractory forms of progressive multiple sclerosis (PMS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.